Valproate as an adjunct to antipsychotics for schizophrenia: a systematic review of randomized trials.
Randomized controlled trials comparing valproate (as a sole, or as an adjunctive compound) to placebo for patients with schizophrenia or schizophrenia-like disorders were summarized in a metaanalysis. It was possible to include only five trials (n = 379) examining valproate as add-on to antipsychotics in this review. Some of the single studies showed inconsistent beneficial effects on some aspects of response, but no overall superiority of valproate augmentation at study endpoints was shown.
Basan
Anja
A
Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Str. 22, 81675 München, Germany. anja.basan@lrz.tum.de
Kissling
Werner
W
Leucht
Stefan
S
D000927:Anticonvulsants / Q000494:pharmacology* / Q000627:therapeutic use*; D014150:Antipsychotic Agents / Q000378:metabolism* / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D016032:Randomized Controlled Trials as Topic; D012559:Schizophrenia / Q000188:drug therapy*; D014635:Valproic Acid / Q000494:pharmacology* / Q000627:therapeutic use*
D000927:Anticonvulsants; D014150:Antipsychotic Agents; D014635:Valproic Acid